Atlas Trials

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Clinical trial NCT03911973 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03911973
Sponsor
Kari Wisinski
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
TNBC - Triple-Negative Breast Cancer
Start date
2019-04-17
Primary completion
2024-07-01
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.